<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
    <title>AZELIS GROUP (+)</title>
    <style type="text/CSS">
        body, #body_style {
            background:#ffffff; color:#000000;
            font-size: 10pt; font-family: arial,helvetica,sans-serif;}
        a, a:link, a:visited {color:#298085; text-decoration:none;font-family:arial} /*optional*/
        table.erratum { color:#444; background-color:#eee; font-size:11px; margin:0 0 0 0; padding:5px; font-style:italic;}
    </style>
</head>
<body>
<style type="text/CSS">
    body, #body_style {
        background:#ffffff; color:#000000;
        font-size: 10pt; font-family: arial,helvetica,sans-serif;}
    a, a:link, a:visited {color:#298085; text-decoration:none;font-family:arial} /*optional*/
    table.erratum { color:#444; background-color:#eee; font-size:11px; margin:0 0 0 0; padding:5px; font-style:italic;}
</style>
<p style="font-weight:normal;color:#000000;"><span style="font-weight:bold">BNP PARIBAS EXANE RESEARCH</span><br>
    <span style="font-family:arial, Helvetica, sans-serif; font-weight:normal;"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__cube.cib.bnpparibas_slink_pKqGSvqjXs8gUQIf&amp;d=DwMCaQ&amp;c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&amp;r=MzuADoFkl_fAwHkKJU3ka8N1EmhTE9zBu3rgmYceNflgkQ0CJ8DBmnHeK145xYjW&amp;m=2FezVFVNB_kC_Qg7z9FIaXtApbsaEDBRAVJjG0erY2ICVTvC-yPjnRLNAx4cThNk&amp;s=0aCFMzaPNDl9ttxSbx8Z3s4KRhbAZL5VMKLogefgWeA&amp;e=" style="color:#298085; text-decoration:underline;">View&nbsp;(14p)</a>
<span style="color:#7b7b7b;">• </span><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__cube.cib.bnpparibas_slink_pKqGSvfO2mTdUNmE&amp;d=DwMCaQ&amp;c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&amp;r=MzuADoFkl_fAwHkKJU3ka8N1EmhTE9zBu3rgmYceNflgkQ0CJ8DBmnHeK145xYjW&amp;m=2FezVFVNB_kC_Qg7z9FIaXtApbsaEDBRAVJjG0erY2ICVTvC-yPjnRLNAx4cThNk&amp;s=iPb523MTZWE2HrT1dCyzy8gI-cGrcnyMwDLBmJNUMTo&amp;e=" style="color:#298085; text-decoration:underline;">Financial
 Highlights</a> </span><br>
</p>
<table border="0" cellspacing="0" cellpadding="3" width="auto">
    <tbody>
    <tr>
        <td bgcolor="#e0eded" style="margin:0;padding:3;color:#298085; font-weight:bold;">
            <a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__cube.cib.bnpparibas_slink_pKqGSvqjXs8gUQIf&amp;d=DwMCaQ&amp;c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&amp;r=MzuADoFkl_fAwHkKJU3ka8N1EmhTE9zBu3rgmYceNflgkQ0CJ8DBmnHeK145xYjW&amp;m=2FezVFVNB_kC_Qg7z9FIaXtApbsaEDBRAVJjG0erY2ICVTvC-yPjnRLNAx4cThNk&amp;s=0aCFMzaPNDl9ttxSbx8Z3s4KRhbAZL5VMKLogefgWeA&amp;e=" style="font-size: 11pt;color:#298085; font-weight:bold; text-decoration:none;">AZELIS
                GROUP (+) </a></td>
    </tr>
    </tbody>
</table>
<div><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__cube.cib.bnpparibas_slink_pKqGSvqjXs8gUQIf&amp;d=DwMCaQ&amp;c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&amp;r=MzuADoFkl_fAwHkKJU3ka8N1EmhTE9zBu3rgmYceNflgkQ0CJ8DBmnHeK145xYjW&amp;m=2FezVFVNB_kC_Qg7z9FIaXtApbsaEDBRAVJjG0erY2ICVTvC-yPjnRLNAx4cThNk&amp;s=0aCFMzaPNDl9ttxSbx8Z3s4KRhbAZL5VMKLogefgWeA&amp;e=" style="font-size: 11pt;color:#298085; font-weight:bold; text-decoration:none;">Chicken
    cyclical</a></div>
<span style="color:#7b7b7b;">TP:&nbsp;EUR25</span> <span style="color:#7b7b7b;">• </span>
<span style="color:#7b7b7b;">Upside:&nbsp;22%</span> <span style="color:#7b7b7b;">• </span>
<span style="color:#7b7b7b;">Price:&nbsp;EUR20.4 (19 Feb. 25)</span>
<p style="font-family:arial, Helvetica, sans-serif;color:#000000"><span style="color:#000000;font-weight:bold;"><b>What did we learn from H2'24?</b></span><br>
    Azelis reported a mixed Q4 update, with P&amp;L metrics largely in-line, but Net Debt &gt;EUR100m above our forecast on deferred M&amp;A payment including some minority buy-outs. Following stabilisation in H1 and the return to modest growth in Q3, Q4 showed clear growth
    (EBITA was up 11% y/y, in-line with consensus, including 7% organic growth). Management highlighted that order books into Q1 looked promising, without ground to fear that this could be driven by pre-buy ahead of tariffs implementation.
    <br>
</p>
<p style="font-family:arial, Helvetica, sans-serif;color:#000000"><span style="color:#000000;font-weight:bold;"><b>How does it change our investment view?</b></span><br>
    Our central case for the sector is that we are going to see a slow gradual recovery, which is unlikely to be enough to bring back supply/demand into tension for commodity chems. We therefore look for businesses with ability to demonstrate growth through operating
    leverage and structural drivers, at a reasonable price. We think Azelis fits that bill, following two lacklustre years. We continue to see the valuation discount to IMCD as unjustified, although we understand liquidity constraints and the stock overhang. Given
    FCF profile, we are not particularly concerned by the leverage situation, although we are mindful that a capital increase may be warranted should the M&amp;A pipeline evolve from the current 'tuck-in' framework. We see Azelis as a so-called 'chicken cyclical',
    i.e. one that is less volatile. <br>
</p>
<p style="font-family:arial, Helvetica, sans-serif;color:#000000"><span style="color:#000000;font-weight:bold;"><b>EBITA upped, net debt up, EPS trimmed, target unchanged
</b></span><br>
    We up our sales/GP assumptions from a blend of FX and M&amp;A, driving c2% upgrades to EBITA forecasts. We trim EPS marginally on the back of higher interest costs, and our DCF-based target stays unchanged at EUR25.<br>
</p>
<p style="font-family:arial, Helvetica, sans-serif;color:#000000"><span style="color:#000000;font-weight:bold;"><b>+ questions for management inside</b></span><br>
</p>
<br>
<p style="font-family:arial, Helvetica, sans-serif;">Laurent Favre, CFA<br>
    (+44) 203 430 8518 <br>
    <a href="mailto:laurent.g.favre@uk.bnpparibas.com" style="text-decoration:none; color:#298085;">laurent.g.favre@uk.bnpparibas.com</a>
</p>
<p style="font-family:arial, Helvetica, sans-serif;"></p>
<div>&nbsp;</div>
<table border="0" cellspacing="0" cellpadding="3" width="100%">
    <tbody>
    <tr>
        <td style="border-top:1px solid black;border-bottom:1px solid black;margin:0;padding:0;font-weight:bold;font-size:10pt">
            <a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__cube.cib.bnpparibas&amp;d=DwMCaQ&amp;c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&amp;r=MzuADoFkl_fAwHkKJU3ka8N1EmhTE9zBu3rgmYceNflgkQ0CJ8DBmnHeK145xYjW&amp;m=2FezVFVNB_kC_Qg7z9FIaXtApbsaEDBRAVJjG0erY2ICVTvC-yPjnRLNAx4cThNk&amp;s=c24jLBVqOcHw1YHyNX8JR__a2QXB8odRuOWSLrTiB2w&amp;e=" style="color:#298085;font-weight:bold; font-size:10pt"><span style="color:black;font-weight:bold">CUTTING-EDGE
 DATA - Click here to access </span>CUBE</a> </td>
    </tr>
    </tbody>
</table>
<div>&nbsp;</div>
<span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;color:#696969;">You have subscribed to our research -
<a style="font-size: 10pt; font-family: arial,helvetica,sans-serif;color:#696969;" href="https://urldefense.proofpoint.com/v2/url?u=https-3A__cube.cib.bnpparibas_unsubscribe_info_qrdJHc-2DqPBVtfKUSr4al8W5CXB66id2VsxDB1BCzH2HzmCrz-2DCRlj9ihWppq4MsV07fUAYNjQzQx&amp;d=DwMCaQ&amp;c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&amp;r=MzuADoFkl_fAwHkKJU3ka8N1EmhTE9zBu3rgmYceNflgkQ0CJ8DBmnHeK145xYjW&amp;m=2FezVFVNB_kC_Qg7z9FIaXtApbsaEDBRAVJjG0erY2ICVTvC-yPjnRLNAx4cThNk&amp;s=0CVbm2zGnopDOhC7rSbNcIOx1NNRGx0HXBuSWpX0ovM&amp;e=">
click here to unsubscribe</a></span><br>
<p style="font-family:arial, Helvetica, sans-serif; font-size:12px; color:#696969;">
    This e-mail may contain confidential and/or privileged information. If you are not the intended recipient (or have received this e-mail in error) please notify the sender immediately and delete this e-mail. Any unauthorised copying, disclosure or distribution
    of the material in this e-mail is prohibited. Please refer to <a href="https://urldefense.proofpoint.com/v2/url?u=http-3A__www.bnpparibas.co.uk_en_email-2Ddisclaimer&amp;d=DwMCaQ&amp;c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&amp;r=MzuADoFkl_fAwHkKJU3ka8N1EmhTE9zBu3rgmYceNflgkQ0CJ8DBmnHeK145xYjW&amp;m=2FezVFVNB_kC_Qg7z9FIaXtApbsaEDBRAVJjG0erY2ICVTvC-yPjnRLNAx4cThNk&amp;s=vW0CSo0o4qTsXrY_0ShcbA6EaAte3qvJd8iYneodqrI&amp;e=" style="color:#298085; text-decoration:none;" target="_new">
    http://www.bnpparibas.co.uk/en/email-disclaimer</a> for additional disclosures. </p>
<img src="https://cube.cib.bnpparibas/alertpix/pKqGSvqjXs8gUQIf" width="1" height="1">
<br>
<br>
This message is intended for the addressee only and may contain confidential or proprietary information. Any use or copying of this message or the information it contains other than by an intended recipient and for the purposes for which it was sent is prohibited.
Hurricane Capital Advisors LLC reserves the right to monitor and archive all e-mail communications as legally allowed.
</body>
</html>
